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Abstract
Background: The widespread antimicrobial resistance of Neisseria gonorrhoeae is a serious problem for the
treatment and control of gonorrhoea. Many of the previously effective therapeutic agents are no longer viable.
Because N. gonorrhoeae infections are not reportable in Germany, only limited data on disease epidemiology and
antimicrobial susceptibility patterns are available. The Gonococcal Resistance Network (GORENET) is a surveillance
project to monitor trends in the antimicrobial susceptibility of N. gonorrhoeae in Germany in order to guide
treatment algorithms and target future prevention strategies.
Methods: Between April 2014 and December 2015, data on patient-related information were collected from
laboratories nationwide, and susceptibility testing was performed on 537 N. gonorrhoeae isolates forwarded from
the network laboratories to the Conciliar Laboratory for gonococci. Susceptibility results for cefixime, ceftriaxone,
azithromycin, ciprofloxacin and penicillin were defined according to EUCAST 4.0 standards. Percentages, medians
and interquartile ranges (IQR) were calculated.
Results: Altogether, 90% of isolates were from men. The median age was 32 (IQR 25–44) years for men and 25
(IQR 22–40) years for women (p-value < 0.001). The most frequently tested materials among men were urethral
(96.1%) and rectal swabs (1.7%), and among women, it was mainly endocervical and vaginal swabs (84.3%). None
of the isolates were resistant to ceftriaxone. Furthermore, 1.9% (in 2014) and 1.4% (in 2015) of the isolates were
resistant to cefixime, 11.9% and 9.8% showed resistance against azithromycin, 72.0% and 58.3% were resistant to
ciprofloxacin, and 29.1% and 18.8% were resistant to penicillin.
Conclusions: Resistance to ceftriaxone was not detected, and the percentage of isolates with resistance to
cefixime was low, whereas azithromycin resistance showed high levels during the observation period. The rates
of ciprofloxacin resistance and penicillin resistance were very high across Germany. Continued surveillance of
antimicrobial drug susceptibilities for N. gonorrhoeae remains highly important to ensure efficient disease management.
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Background
The worldwide development of antimicrobial resistance
in Neisseria gonorrhoeae is a serious problem for the
treatment and control of gonorrhoea. Treatment oppor-
tunities are dramatically limited because many of the
previously recommended therapeutic agents are no lon-
ger effective.
The World Health Organization (WHO) [1], the
Centers for Disease Control and Prevention (CDC) [2],
and the European Centre for Disease Prevention and
Control (ECDC) [3] have called for action to confine the
spread of multidrug-resistant N. gonorrhoeae by enhan-
cing the surveillance system of N. gonorrhoeae suscepti-
bility testing and by strengthening laboratory capacities
to perform culture and antimicrobial resistance testing.
Representative coverage of collected data, unified N.
gonorrhoeae susceptibility testing methods and interpret-
ation standards are of great importance [4–6].
Extended spectrum cephalosporins (ESCs) are the last
agents effective against N. gonorrhoeae. However, resist-
ance to ESCs is increasingly common [7–13], causing
concern that the efficacy of this substance group could
expire in the near future [5–10]. Due to the worldwide
rising resistance of N. gonorrhoeae against cefixime in
recent years, the treatment guidelines needed to be
changed accordingly. Thus, cefixime is no longer recom-
mended as first-line therapy in many countries [14–16]
and new therapy guidelines and action plans have been
developed to keep gonorrhoea a treatable disease. In
2014 the German STI Society implemented new therapy
guidelines for Germany. These guidelines recommend
the use of the ESC ceftriaxone (1000 mg single dose i.m.
or i.v.), now in combination with azithromycin as dual
therapy (1.5 g single dose p.o.), as the first-line treatment
[17]. The use of cefixime (800 mg single dose p.o.)
should be reserved for cases where parenteral treatment
is not possible and ideally after susceptibility testing.
Because gonorrhoea is not a notifiable disease in
Germany, only very limited data about epidemiology and
antimicrobial resistance against N. gonorrhoeae are
available. Furthermore, no standard operating proce-
dures or unified protocols for N. gonorrhoeae suscepti-
bility testing have been established in Germany. To
date, information about N. gonorrhoeae susceptibility
can be derived from several cross-sectional, regionally
limited studies [18–21] through the German antibiotic
resistance surveillance programme (ARS) and 100–120
isolates submitted to Euro-GASP yearly through the
Consiliary Laboratory (CL) for gonococci [22]. Within
this Euro-GASP collection, isolates resistant against
ceftriaxone (MIC >0.125 mg/L) have been observed in
Germany. Resistance against ceftriaxone was shown by
6.5% (n = 7) of all German Euro-GASP isolates in 2011,
while in the following years 2012–2014, one isolate per
year (1%) could be identified with ceftriaxone resistance.
Cefixime resistance (MIC >0.125 mg/L) in German Euro-
GASP isolates ranged between 5.7% and 12.9% (n = 13,
11.9% in 2010; n = 11, 10.2% in 2011; n = 6, 5.7% in 2012;
n = 13, 12.9% in 2013) [22]. In 2014, there was no detec-
tion of cefixime-resistant isolates in Euro-GASP.
To implement continuous routine data collection on
epidemiology and antimicrobial susceptibility testing for
N. gonorrhoeae in German laboratories (aim 1) and to
collect isolates for testing in the German CL for gono-
cocci with unified methodology (aim 2), we set up a N.
gonorrhoeae resistance network (GORENET).
We analysed the data and isolates collected through
GORENET in 2014 and 2015 to guide treatment algo-
rithms and targeted prevention strategies in Germany.
Methods
To characterise laboratories testing for N. gonorrhoeae
in Germany and indicate laboratories for recruitment,
we performed a cross-sectional survey between June and
August 2013, as described previously [23]. From the
laboratories that expressed an interest in participating,
we recruited private and hospital laboratories for
GORENET, prioritizing those with a wider catchment
area and a higher number of N. gonorrhoeae tests per
quarter. The laboratories in Germany have no prede-
fined catchment areas, and practitioners are free to
choose laboratories for cooperation. For a better geo-
graphical coverage of the data, we strove to recruit
laboratories from all regions in Germany and laborator-
ies that use any gradient Etest for N. gonorrhoeae
susceptibility testing, at least for azithromycin, ceftriax-
one and cefixime. Participation was voluntary, and
there was no financial compensation for laboratories to
participate in the study. The data collection protocol
was confirmed by the data protection officer at the
Robert Koch Institute (RKI), Berlin. Additional approval
from an ethics committee was deemed to be unnecessary.
Continuous routine data collection
From GORENET network laboratories, continuous
routine data on all samples tested for N. gonorrhoeae
antimicrobial susceptibility were collected between
April 2014 and December 2015. The network laborator-
ies submitted data to the RKI (further labelled as sam-
ples). The collected data included sample identification
number, information on test results, sampled material
(urethral swab, urine, vaginal swab, cervical swab, rectal
swab, pharyngeal swab, and other material), date of
sampling, date of testing, district code, gender and year
of birth. If the district code of the patient was not
available, we used the code of the laboratory instead.
Based on the year of birth, we calculated the person’s
age at the time of sampling. If the date of testing was
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not available, we used the date when the isolate was
received in the CL.
Data were transmitted electronically to the RKI.
Laboratories entered the data either in an online ques-
tionnaire (VOXCO Command Center 3) or in a prefor-
matted Excel spreadsheet (.xls). Data on N. gonorrhoeae
susceptibility from laboratories willing to participate in
GORENET but already submitting their susceptibility data
(including data on a wide range of other agents) to the
German Antibiotic Resistance Surveillance Programme
(ARS) were extracted from the ARS database. We per-
formed plausibility checks on all reported data.
Based on the district codes, we described the geo-
graphical distribution of the samples tested for N.
gonorrhoeae antimicrobial susceptibility. Each district
code or respective 3-digit postal code corresponded to
one district in Germany. We used samples tested for
susceptibility from participating laboratories to describe
tested persons by gender, age, sampled material and
treating specialist. Susceptibility results from participating
laboratories are used for national surveillance, but not
presented in this paper.
An overview of the analysis of samples tested for
N. gonorrhoeae susceptibility in network laboratories
is given in Table 1.
Isolate collection and susceptibility testing
The network laboratories were asked to send N.
gonorrhoeae isolates from the samples tested for anti-
microbial susceptibility between April 2014 and December
2015 to the CL for extended and comparative susceptibility
testing (further labelled as isolates). There were no criteria
used to preselect isolates that should be sent to CL.
The sample identification number was used to link iso-
lates to samples. For all received isolates, we confirmed
N. gonorrhoeae by using a combination of culture on
non-selective agar medium, rapid oxidase production
assays and determining the presence of Gram-negative
diplococci using microscopy and the Phadebact Monoclo-
nal GC OMNI Test (Pharmacia Diagnostics, Piscataway,
NJ, USA). Susceptibility testing was performed and
MIC were detected by using Etest (bioMérieux SA,
Marcy-l’Étoile, France) according to the manufacturer’s
instructions for ceftriaxone, cefixime, azithromycin, peni-
cillin and ciprofloxacin. To define resistance, we used the
criteria of the European Committee on Antimicrobial Sus-
ceptibility Testing EUCAST 4.0 (2014) [24]. The presence
of beta-lactamase enzyme production, which provides
high-level resistance to penicillins, was detected by using
the nitrocefin test (BBL DrySlide™, Becton, Dickinson, NJ,
USA). Isolates testing positive for beta-lactamase were de-
fined as penicillinase-producing N. gonorrhoeae (PPNG).
The working stock of N. gonorrhoeae isolates was
stored at −80 °C. N. gonorrhoeae strains ATCC 49226
and WHO-reference strains G, K, M, O and P were used
with each batch of Etest as quality controls [25]. Ceftri-
axone and cefixime were tested twice when the MIC was
≥0.125 mg/L. Isolates tested in the CL were characterized
by their resistance patterns.
An overview of the analysis of isolates tested in CL is
given in Table 1. Note that a direct comparison of his-
torical German data with current GORENET data was
not possible because different methods for isolate col-
lection were in place before GORENET was rolled out
and the geographical coverage was different.
For categorical variables we calculated percentages
and, for continuous variables, medians together with
interquartile ranges (IQR) were determined. Percentages
were compared by Chi-squared or Fisher’s exact tests,
and medians were compared with the Wilcoxon-Mann-
Whitney test, where applicable. The Kruskal-Wallis test
was used to compare continuous variables between
more than two categories. Significance level was set at
a p-value < 0.05.
Results
Of the 100 laboratories that were interested in partici-
pating in GORENET, 31 were selected for recruitment,
and 23 agreed and reported data to GORENET. The
reasons for declining participation in GORENET were
not using the Etest for N. gonorrhoeae susceptibility
Table 1 Isolates tested for susceptibility in network laboratories and in CL, number of laboratories and isolates included in analysis
and description of performed analysis for each data source
Number of
laboratories




Samples tested for N. gonorrhoeae
susceptibility in network laboratories
23 1654 727 927 Samples Geographical, age and gender
distribution. Sampled material
and treating specialist
Isolates tested in CL 16 537 261 276 Isolates Susceptibility for ceftriaxone,
cefixime, azithromycin, penicillin
and ciprofloxacin. Presence of
beta-lactamases
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testing (n = 5) and too much time and effort needed for
participation (n = 3).
Continuous routine data collection
Twenty-three participating laboratories reported to the
RKI in total 1654 N. gonorrhoeae samples tested for sus-
ceptibility. Of them, 727 were collected from April to
December 2014, and 927 were collected from January to
December 2015. Overview of the reported samples is
given in Table 1.
The number of reported samples varied between 2
and 305 per laboratory, with a median of 43 samples
(IQR 24–86). In total 47.1% of the samples were reported
by three laboratories, which provided information on 209
(in Hamburg), 265 (in Berlin) and 305 (in North Rhine-
Westphalia) samples, respectively.
The number of reported N. gonorrhoeae samples
varied by administrative district between 1 and 209
(Fig. 1). The three laboratories submitting the majority
of the data were located in the areas with >50 samples.
Central and northern Germany were represented
equally. Data from southern Germany mostly originated
from the larger cities.
Overall, 90.0% of samples tested for susceptibility in
network laboratories were from men; 9.5% were from
women and in nine samples, information on gender
was not available. The median age of tested men and
women was 33 (IQR 25–44) and 27 (IQR 22–40)
years respectively (p-value < 0.001). The distribution of
Fig. 1 Distribution of N. gonorrhoeae samples by district in Germany. One thousand, six hundred and fifty-four samples from April 2014 to December
2015 (1366 defined by district code of the patient, 288 defined by district code of the laboratory). Map developed with RegioGraph Software
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N. gonorrhoeae susceptibility testing by age group and
gender is displayed in Fig. 2.
Most tested samples from men were from urethral
(96.1%) and rectal swabs (1.7%), while among women
samples came from predominately endocervical or vagi-
nal swabs (84.3%). Most of the samples tested from
men were ordered by urologists (74.4%) and from
women by gynaecologists (79.7%). Distribution by gen-
der (p-value = 0.25), age (p-value = 0.28 for men and p-
value = 0.87 for women), tested material (p-value = 0.15
for men and p-value = 0.07 for women) and ordering
specialist (p-value = 0.63 for men and p-value = 0.73 for
women) did not differ between the years 2014 and 2015.
Isolate collection and susceptibility testing
From the recruited 23 laboratories submitting informa-
tion on samples tested for N. gonorrhoeae susceptibility,
16 sent isolates to the CL. We received 261 viable iso-
lates collected between April and December 2014 and
276 viable isolates collected between January and De-
cember 2015. It was determined that 91.4% of isolates
were from men, 8.4% were from women, and for one of
the samples the gender was unspecified. The median age
was 33 (IQR 26–43) for isolates from men and 28 (IQR
23–41) for isolates from women. These 537 isolates were
tested for susceptibility in the CL. An Overview of the
isolates tested in CL is given in Table 1. The results of
the AMR testing of all isolates are summarized in
Table 2. The percentage of resistant, intermediate and
susceptible isolates did not significantly differ by age or
gender.
No resistance to ceftriaxone (MIC >0.125 mg/L) was
detected in 2014 or 2015 (Fig. 3). In 2014, two isolates
showed MICs at the estimated breakpoint of 0.125 mg/
L. One of these isolates displayed further resistance to
cefixime, azithromycin and ciprofloxacin and showed an
intermediate test result to penicillin (isolate 1, Table 3).
Another isolate displayed resistance to ciprofloxacin
and penicillin, while it was intermediate to azithromy-
cin and had a MIC value at the breakpoint for cefixime
(isolate 10, Table 3).
Altogether, 1.9% (n = 5) in 2014 and 1.4% (n = 4) in 2015
of the isolates displayed resistance (MIC >0.125 mg/L) to
cefixime. The majority of isolates (62.5% in 2014 and
77.9% in 2015) showed low MICs of ≤0.016 mg/L to
cefixime (Fig. 4). In 2014, 3.8% (n = 10) and in 2015,
1.4% (n = 4) of the isolates had a MIC of 0.125 mg/L at
the estimated breakpoint.
All isolates with resistance to cefixime displayed re-
sistance to ciprofloxacin. Three of the nine cefixime-
resistant strains also showed resistance to azithromycin.
No cefixime-resistant strain was susceptible to penicil-
lin (3 resistant, 6 intermediate).
One cefixime-resistant isolate (MIC 0.25 mg/L) dis-
played additional resistance against azithromycin and
ciprofloxacin, intermediate susceptibility against penicil-
lin and showed reduced susceptibility to ceftriaxone at
the breakpoint of MIC 0.125 mg/L (isolate 1, Table 3).
All isolates displaying resistance to cefixime were from
men.
A total of 11.9% (2014) and 9.8% (2015) of the isolates
showed resistance against azithromycin (MIC >0.5 mg/L).
In addition, there was a high percentage of N. gonorrhoeae
strains with intermediate susceptibility (33.7% in 2014 and
28.3% in 2015) and the MIC distribution of the susceptible
strains appeared closer to intermediate breakpoint (MIC
>0.38 mg/L) (Fig. 5). The MICs of resistant strains were
mostly low and showed a distribution concentrating
around the breakpoint (MIC >0.5 mg/L).
In 2015, one isolate displayed high-level resistance to
azithromycin (MIC >256 mg/L). This isolate also
showed high-level resistance to penicillin and resist-
ance to ciprofloxacin, but was susceptible to ceftriax-
one and cefixime.
Fig. 2 N. gonorrhoeae samples tested in participating laboratories, by age group and gender, n = 1642
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The percentage of strains with resistance to ciprofloxa-
cin (MIC >0.06 mg/L) was 72.0% in 2014 and 58.3% in
2015 (Table 2).
Overall, 29.1% of the isolates in 2014 and 18.8% in
2015 displayed resistance to penicillin. In addition, there
was a very high rate of intermediate N. gonorrhoeae
strains (Table 2).
Nitrocefin testing for the detection of beta-lactamase
activity in N. gonorrhoeae was performed in 83.5%
(n = 218) of isolates in 2014. All 276 isolates (100%)
were tested for beta-lactamase activity in 2015. High-
level plasmid-mediated resistance against penicillin
(penicillinase producing N. gonorrhoeae, PPNG) was
found in 25% of all tested strains in 2014 and in 14%
of the strains in 2015.
Discussion
Using GORENET we aimed at two targets concerning
gonococcal infections: data collection on disease epi-
demiology and monitoring of resistance patterns with
unified methodology.
We were able to implement a nationwide data collec-
tion of all performed N. gonorrhoeae susceptibility test-
ing in the participating laboratories. Routine data
collection on all performed N. gonorrhoeae susceptibility
tests together with epidemiological information, like
age and gender, was not in place until GORENET
surveillance.
Before starting GORENET, the CL collected isolates
from a range of laboratories. This pre-existing network
was expanded within GORENET, and the number of
collected isolates increased substantially.
We were able to set up electronic data collection for
all samples tested for N. gonorrhoeae susceptibility in the
participating laboratories. Timely transmitted data are a
good tool for monitoring N. gonorrhoeae susceptibility
dynamics. Due to data protection issues, the collected
epidemiological information was limited and important
information, such as data regarding the transmission
route, therapeutic regimen and therapeutic success,
could not be gathered.
We reached a relatively even geographical representa-
tion of all regions, but the coverage in central and
southern Germany should be increased further.
In routine data collection from the network labora-
tories, we found that over 90% of all samples tested for
N. gonorrhoeae susceptibility were from men, similar to
several other European countries [22]. This percentage
Table 2 Number and percentage of N. gonorrhoeae isolates testing susceptible, intermediate and resistant against cefixime,
ceftriaxone, azithromycin, penicillin and ciprofloxacin, n = 261 for year 2014 and n = 276 for year 2015, *p-value < 0.05
Susceptible Intermediate Resistant
Number (percentage, %) Number (percentage, %) Number (percentage, %)
2014 2015 2014 2015 2014 2015
Cefixime 256 (98.1) 272 (98.6) ∕ ∕ 5 (1.9) 4 (1.4)
Ceftriaxone 261 (100) 276 (100) ∕ ∕ 0 (0) 0 (0)
Azithromycin 142 (54.4) 171 (62.0) 88 (33.7) 78 (28.3) 31 (11.9) 27 (9.8)
Ciprofloxacin* 73 (28.0) 114 (41.3) 0 (0) 1 (0.4) 188 (72.0) 161 (58.3)
Penicillin* 27 (10.3) 40 (14.5) 158 (60.5) 184 (66.7) 76 (29.1) 52 (18.8)
Fig. 3 Distribution of minimum inhibitory concentrations for ceftriaxone, n = 261 for year 2014 and n = 276 for year 2015
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was 84% in previous studies in Germany [15], and we
can assume that at least half of all isolates from men
are attributable to men having sex with men (MSM),
comparable to other European countries [22]. Never-
theless, women might still be underrepresented in our
sample. This seems possible because men are more
often symptomatic and might therefore be tested more
often than women [14]. We aim to collect data on
transmission routes from physicians to better interpret
the collected data.
We also found that the median age of tested men was
slightly higher than that of tested women. Again, Euro-
GASP data and other previous data from Germany have
reported findings [18, 21, 22] similar to our results. In
countries that reported the risk of transmission, the pro-
portion of men aged >25 years was higher among MSM
than among heterosexual men. This might explain the
higher median age of the tested men in our sample. As
N. gonorrhoeae is not reportable in Germany, we were
not able to compare whether the N. gonorrhoeae AMR
test distribution by age corresponded to the age groups
most affected by gonorrhoea.
We exclusively analysed susceptibility data from the
CL testing because presently Germany lacks a stand-
ard operation protocol and regular quality assurance
for N. gonorrhoeae testing for all laboratories. From a
cross-sectional survey among laboratories performing
N. gonorrhoeae diagnostics we know that 55% of all la-
boratories (76% of private laboratories) are accredited
and 19% are certified [23]. However, due to the use of
different methods, standards and test panels it is
unknown if there are substantial differences in quality
of testing, and GORENET will be a useful tool for
quality assurance in the future.
Susceptibility testing in the CL enabled the monitoring
of N. gonorrhoeae antimicrobial resistance detected by a
unified methodology. Age and gender distribution of the
Table 3 Minimum inhibitory concentrations (MIC) of cefixime,
ceftriaxone, azithromycin, ciprofloxacin and penicillin for isolates
with resistance to cefixime or with MICs at the breakpoint for
resistance to cefixime (n = 24)
Minimum inhibitory concentration (MIC)
Isolate Cefixime Ceftriaxone Azithromycin Ciprofloxacin Penicillin
1 0.25 0.125 0.75 32 1
2 0.19 0.047 1 0.25 32
3 0.19 0.094 0.75 32 3
4 0.19 0.023 0.19 32 0.75
5 0.19 0.047 0.125 32 0.75
6 0.19 0.032 0.19 32 1.5
7 0.19 0.032 0.094 12 0.75
8 0.19 0.032 0.19 16 1
9 0.19 0.023 0.125 16 0.75
10 0.125 0.125 0.5 32 2
11 0.125 0.064 1 32 1
12 0.125 0.064 1 32 2
13 0.125 0.032 0.19 32 0.75
14 0.125 0.032 0.19 32 0.75
15 0.125 0.032 0.19 32 0.5
16 0.125 0.032 0.125 32 1.5
17 0.125 0.023 0.125 32 0.38
18 0.125 0.023 0.19 32 0.75
19 0.125 0.023 0.19 32 0.5
20 0.125 0.023 0.125 16 0.75
21 0.125 0.023 0.094 12 0.75
22 0.125 0.016 0.25 32 0.75
23 0.125 0.012 0.125 12 0.38
24 0.016 0.006 256 12 32
Fig. 4 Distribution of minimum inhibitory concentration for cefixime, n = 261 for year 2014 and n = 276 for year 2015
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tested isolates did not differ from all samples tested for
susceptibility in the participating laboratories.
No resistance to ceftriaxone was detected in 2014 and
2015 in isolates collected with GORENET, and only two
isolates showed MICs at the estimated breakpoint of
0.125 mg/L.
Previous German publications also did not show not-
able levels of ceftriaxone resistance or ESC resistance
[18–21] in Germany. However, within the Euro-GASP
collection, there was one exception in 2011, when 6.5%
of German strains were resistant against ceftriaxone. In
the following years 2012–2014, there were no notable
levels of ceftriaxone resistance observed [18, 21, 22] in
Germany by the Euro-GASP surveillance.
Currently, parenterally administered ceftriaxone re-
mains an effective treatment option for gonorrhoea in
Germany. Similar data have been published from surveil-
lance systems in other countries [13, 26].
The percentage of strains with resistance to cefixime
remained moderate within the GORENET (<2%), and
low MIC values were predominant. German Euro-GASP
data from 2014 correspond to this GORENET observa-
tion. In 2014 no cefixime-resistant isolate from Germany
was detected within the Euro-GASP surveillance [22].
Compared with previous German data from Euro-GASP,
this is a decrease from the years 2009–2013, when resist-
ance rates from 5.7% to 12.9% were detected [22]. The
decreasing number of strains resistant to cefixime could be
observed not only in GORENET: European Euro-GASP
data from 2014 and surveillance reports from the United
Kingdom, the United States and Canada showed the same
trend to less ESC-resistant isolates [26–29]. The decrease
in gonococcal resistance to cefixime in 2014/15 suggests
that clinicians in Germany may have avoided prescribing
this antibiotic as a first-line treatment after the new therapy
guidelines were published. However, changes in resistance
patterns develop incrementally and are usually not detected
so fast.
A presumptive explanation for this observation is the
eradication of previously undetected reservoirs [27, 30].
Especially extragenital infections, which are oftentimes
asymptomatic, difficult to culture and difficult to treat,
are a constant reservoir for the spread of gonorrhoea
[9, 30, 31]. Due to regular use of highly sensitive mo-
lecular diagnostic tests, like nucleic acid amplification
tests (NAAT), in the routine diagnostic, detection of
gonococcal infections was improved. Extragenital infec-
tions and subclinical urogenital infections are therefore
more often confirmed and can be successfully treated
[31]. The adjustment of treatment guidelines for ceftriax-
one as first-line therapy seems to provide here an additional
benefit. Sufficient treatment of these infections prevents a
selection of resistant clones and might be a reason for the
decrease of cefixime-resistant gonococci [27, 28, 30].
Molecular typing studies, performed with N. gonorrhoeae
multiantigen sequence typing (NG-MAST, http://www.ng-
mast.net) [32], showed one sequence type (ST1407), which
was the most frequently observed sequence type associated
with ESC- and multi-resistance [33–35]. Therefore, a fur-
ther reason for the decrease of cefixime resistance could be
a replacement of this multidrug-resistant N. gonorrhoeae
clone ST1407 by clones with different resistance patterns
within the infected population [27]. This could be an effect
of the sufficient treatment or, as the Euro-GASP authors
pointed out, be caused by impaired reinfection with the
same clone due to a partial immunity and needs to be
evaluated by future typing studies [27]. Additional moni-
toring and a molecular typing study within GORENET in
the next years are therefore intended.
Multidrug resistance was not detected regularly in
GORENET. Only one cefixime-resistant isolate displayed
further resistance to azithromycin and ciprofloxacin,
Fig. 5 Distribution of minimum inhibitory concentration for azithromycin, n = 261 for year 2014 and n = 276 for year 2015
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intermediate susceptibility to penicillin and a reduced sus-
ceptibility to ceftriaxone at the breakpoint MIC of
0.125 mg/L. Nevertheless, the combination of resistances
is particularly alarming and should be monitored further.
A high prevalence of resistance was detected for azi-
thromycin. Although we observed mostly resistance near
the breakpoint (MIC >0.5 mg/L), this trend is concern-
ing. In addition, there was a high rate of intermediate N.
gonorrhoeae strains: 40–45% of the strains were not fully
susceptible to azithromycin. Germany’s data from previ-
ous years [22] shows that the level of azithromycin re-
sistance was mostly under 5%. The first-line use of
azithromycin is very common in STI treatment regimes,
especially as a syndromic treatment before or without
confirmation of the pathogenic agent. This might ex-
plain the increase in azithromycin resistance in the last
several years, but data on prescriptions in Germany are
not published.
In 2015, we detected the first case of a high-level azi-
thromycin resistant N. gonorrhoeae strain in Germany,
with a MIC >256 mg/L. This isolate was susceptible to
ceftriaxone and cefixime but showed high-level resist-
ance to penicillin and resistance to ciprofloxacin. As ris-
ing resistance rates to azithromycin are increasingly
observed globally [22, 26] and high-level azithromycin
resistance is reported worldwide [35–43], azithromycin
is not suitable for first-line treatment. If azithromycin is
used as a single-drug treatment in cases of severe peni-
cillin/cephalosporin anaphylaxis, susceptibility testing
prior to treatment should be performed.
According to current treatment guidelines, dual therapy
with ceftriaxone and azithromycin is recommended, using
two antimicrobial agents with different mechanisms of ac-
tion [5, 44]. Currently, there is no alternative to this dual
treatment regime. Ultimately, we will need to discuss
whether we have to abandon dual therapy with azithromy-
cin if the trend of increasing azithromycin resistance re-
mains in the years to come [9, 45].
The resistance rates to ciprofloxacin were constantly
high in Germany, although a drop was detectable in the
surveillance period. A high prevalence of resistance to
ciprofloxacin has also been found in Europe and world-
wide since the late 1990s [22]. The drug is therefore not
recommended for therapeutic use in Germany.
Resistance to penicillin has been prevalent for many
decades worldwide. Nearly 25% of all isolates displayed
resistance to penicillin and an additional 64% showed
intermediate susceptibility in the GORENET surveillance
data. Accordingly, approximately 90% of the strains were
not fully susceptible to penicillin in Germany. High-level
plasmid-mediated resistance to penicillin was also regu-
larly observed but decreased within the surveillance
period from 25.9% to 14%, an observation that requires
further monitoring.
We have several limitations in our data. First, within
the GORENET data collection scheme, we were unable
to collect more detailed epidemiological information,
such as the risk of transmission, special symptoms,
therapy strategies and treatment success rates. Usually,
laboratories in Germany have very limited epidemio-
logical information available, provided by the physicians
in charge, and need to treat these data confidentially due
to strict data-protection regulations.
Second, our data analysis was limited by the small
number of isolates collected compared to the overall
population of Germany.
Third, we cannot exclude selection bias in our data,
because we recruited laboratories based on their catch-
ment area, number of tested N. gonorrhoeae samples
and use of the Etest from a pool of laboratories that
expressed an interest to participate. However, with se-
lected and established network laboratories, which for-
warded all of their received isolates, we diminished a
collection bias from laboratories being more prone to
submit isolates with interesting resistance patterns.
Conclusions
Using GORENET, we were able to implement a nation-
wide collection of all performed N. gonorrhoeae suscepti-
bility data in the participating laboratories and increase
the number of collected isolates retested at the CL for
confirmation and quality assurance. The majority of sus-
ceptibility tests are performed among young men. More
detailed epidemiological information would be beneficial.
The resistance rate to ceftriaxone remains low in
Germany. Therefore, ceftriaxone is still an appropriate
treatment for gonorrhoea at present. In 2014 and 2015,
we found low resistance rates for cefixime in Germany.
However, this needs further monitoring. Resistance to
azithromycin is common and should continue to be
monitored in the future. Except for a small decrease in
AMR towards ciprofloxacin and penicillin, no substantial
changes in the susceptibility patterns between 2014 and
2015 could be detected.
In conclusion, GORENET as a gonococcal antimicro-
bial surveillance in Germany is highly needed. Current
data and ongoing collection of data will be used to up-
date national treatment guidelines and, if necessary, im-
plementation of future prevention measures.
To continue to monitor N. gonorrhoeae susceptibility,
particularly against ESC and azithromycin, the yearly
number of isolates tested in the CL should be substan-
tially increased. Molecular surveillance of the circulating
strains is important for monitoring the current situation,
the evolving resistances and the transmission networks.
Surveillance of susceptibility is essential to ensure
efficient patient management and keep gonorrhoea a
treatable disease.
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